FDA panel favors FluMist for young children

Share this article:
An FDA advisory panel agreed Wednesday that MedImmune’s FluMist nasal spray flu vaccine is safe and effective in children 2 and older. The vaccine is currently approved for patients ages 5 to 49. MedImmune is currently seeking approval for FluMist in patients ages 1 to 5 without a history of wheezing or asthma. Advisory panel members, in a 9 to 6 vote, said company studies show FluMist’s benefits outweighed its risks in children 1 to 5 years old without known respiratory problems. The panel voted 15 to 0 that if a child does wheeze, the vaccine should be used in only those 2 and older. Advisers voted 12 to 3 against recommending FluMist use in wheezy children younger than 2. The FDA isn’t required to follow the advice of its advisory panels but often does. FluMist was first approved in 2003. Sales of the drug reached $36 million in 2006. Last month, MedImmune agreed to be purchased by AstraZeneca for $15.6 billion. Yesterday, a MedImmune investor yesterday filed a lawsuit against the biotech firm and its senior officers and directors claiming the sale benefited them more than ordinary shareholders. MedImmune said it intends to vigorously defend itself. "We believe the board acted in the best interest of the shareholders in its willingness to accept AstraZeneca's offer to acquire the company," MedImmune spokeswoman Jamie Lacey told Reuters. An AstraZeneca spokesman told Reuters the UK drugmaker is confident the deal between the two firms will continue. "This is a matter for MedImmune as AstraZeneca is not party to the suit. However, MedImmune's SEC filing states that it does not believe the suit has any merit. Therefore we are confident that the deal will go ahead," the AstraZeneca spokesman said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...